Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 3:25 PM
Ignite Modification Date:
2025-12-24 @ 3:25 PM
NCT ID:
NCT03630692
Eligibility Criteria:
Inclusion Criteria:
* Adult patient
* Patient with metastatic or locally advanced kidney cancer
* Patient initiating for the first time an oral route anticancer drug : Sutent® (sunitinib), Nexavar® (sorafenib), Afinitor® (everolimus), Votrient® (pazopanib) and Inlyta® (axitinib) and Cabometyx® (cabozantinib)
* Patient having signed an informed consent
* Patient treated outside interventional clinical trial
Exclusion Criteria:
* Patient with cancer other than kidney cancer
* Patient with non-extensive kidney cancer
* Patient treated by surgery, radiotherapy and intravenous chemotherapy exclusively
* Patient unable to undergo protocol monitoring
* Patient included in an interventional trial
* Patient refusing a survey at home or having hearing problems
* Other medical conditions that may interfere with the understanding of the informed consent document, with the assessment of tolerance and the response to questionnaires
* Patient with another condition deemed incompatible with the patient's inclusion into the protocol.
* Patient under guardianship or trusteeship, deprived of liberty, underage patient or pregnant woman
* Patient not affiliated with a social security system beneficiary of such a scheme
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT03630692
Study Brief:
Protocol Section:
NCT03630692